Pseudoexfoliation may be a risk factor for peripheral vascular disease

Article

Cataract and pseudoexfoliation (PEX) patients with a low ankle brachial index (ABI) are at higher risk of peripheral vascular disease (PVD)

Cataract and pseudoexfoliation (PEX) patients with a low ankle brachial index (ABI) are at higher risk of peripheral vascular disease (PVD), according to a study in Eye.

Dr M.R. Praveen et al., Iladevi Cataract and IOL Research Center, Ahmedabad, India, conducted an observational age-matched case-control study of 160 age-related cataract patients who were no less than 60 years old. Forty PEX patients with cataracts were compared with a control group of 120 cataract patients without PEX. The subjects medical history such as hypertension, diabetes mellitus, cerebrovascular stroke and ischaemic heart disease were taken into consideration.

The risk of PVD among the patients was determined through the measurement of ABI by colour Doppler imaging of the brachia and dorsalis pedis artery. From prio knowledge that a low ABI indicates an increased risk of PVD each patient's lowest mean ABI was recorded as the main outcome measure.

The lowest ABI in the controls was 0.98±0.03 and 0.88±0.02 in the PEX group. It was found that there was a strong correlation between presence of PEX and ABI, with the odds of low ABI being 150 times more than the control group.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.